Professor Bradley completed his paediatric infectious diseases training at Stanford University in 1981 and spends his time divided between clinical care, clinical research and national policy. His clinical research priorities are the development of effective therapy for neonates, infants and children with infections caused by multi-drug resistant Gram-negative bacilli and MRSA, working closely with pharmacologists and microbiologists, using pharmacodynamic/ pharmacokinetic modeling techniques for dose optimisation. He is chair of the Scientific Review Committee for a large paediatric clinical trials consortium, I-ACT, working with academic centres, the Food and Drug Administration and the healthcare industry to study new tests, therapies and vaccines for COVID19. He is also on the FDA’s Advisors and Consultants Staff. Professor Bradley was the lead author on the first national guidelines for the treatment of pneumonia in children and is one of the members of the CDClead Influenza Guidelines Committee , as well as the co-chair of the new Pediatric Bone and Joint Infection Guidelines that are currently being written. Additionally, he is the editor and a co-author for “Nelson’s Pediatric Antimicrobial Therapy,” a book on the treatment of paediatric infections